Rezultati postoperativnog preživljavanja pacijenata sa pleuralnim malignim mezoteliomom stadijuma I-II u endemskom području

Tayfun Kermenli,Cebrail Azar

doi:10.24125/sanamed.v15i2.442

Abstract

Introduction: The accepted treatment option for malignant pleural mesothelioma (MPM) is multimodality treatment including surgery, chemotherapy and radiotherapy. In this study, we aimed to evaluate the results of patients who underwent surgical resection for multimodality treatment due to MPM at our clinic between July 2015 and October 2019. Method: The results of 13 patients who underwent surgical treatment for MPM in our clinic were evaluated retrospectively. Patients' demographic structure, regions where they live, symptom presentation, disease localization, biopsy diagnosis, type of surgical treatment, choice of neoadjuvant or adjuvant chemotherapy, postoperative complications and survival outcomes were evaluated. Results: The mean survival time was 19.6 months. Six patients were still under follow-up. One patient whose postoperative pathology was reported as mixed type had the worst survival with 13 months and the best survival was 32 months in the patient who underwent postoperative hyperthermic chemotherapy with pleural decortication. Four patients died due to local recurrence and general condition disorder, and two patients died after peritonitis carcinomatosis and ascites. Conclusion: Epitheloid type multimodality treatment and intrapleural hyperthermic chemotherapy may be a good choice in patients with the stage I and II malignant mesothelioma without surgical comorbidity

Highlights

The accepted treatment option for malignant pleural mesothelioma (MPM) is multimodality treatment including surgery, chemotherapy and radiotherapy
One patient whose postoperative pathology was reported as mixed type had the worst survival with 13 months and the best survival was 32 months in the patient who underwent postoperative hyperthermic chemotherapy with pleural decortication
Epitheloid type multimodality treatment and intrapleural hyperthermic chemotherapy may be a good choice in patients with the stage I and II malignant mesothelioma without surgical comorbidity

Summary

Introduction

The accepted treatment option for malignant pleural mesothelioma (MPM) is multimodality treatment including surgery, chemotherapy and radiotherapy. Asbestos exhibits pathogenic properties depending on the diameter - length, exposure dose, duration of the asbestos fibers deposited on the pleural surface after exposure and the body’s ability to break down asbestos. These results in benign asbestos plaques or malignant pleural mesothelioma (MPM) [1]. Multimodality therapy, which includes thoracic surgery, oncology and radiation oncology, is the accepted world-wide option in the treatment of MPM [5]. It is recommended that surgical + hyperthermic chemotherapy or radiotherapy to be applied only to surgery, followed by chemotherapy and incision areas together [6]

Objectives

Methods

Results

Discussion

Conclusion